Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 5/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29919173 | 1.00 | GAA (0.37) | GAAPKMDAOF2CSNK2A1 | |
| SCHEMBL30542678 | 0.77 | TBXAS1 (0.37) | PKMDAO | |
| SCHEMBL29056338 | 0.77 | AR (0.31) | ALOX15 | |
| SCHEMBL29965334 | 0.75 | ITK (0.39) | — | |
| SCHEMBL23458890 | 0.75 | ITK (0.39) | — | |
| SCHEMBL31515115 | 0.74 | F2 (0.34) | F2 | |
| SCHEMBL23482022 | 0.73 | L3MBTL1 (0.40) | GAA | |
| SCHEMBL23482013 | 0.71 | LOXL2 (0.46) | GAAPKMDAOCSNK2A1 | |
| SCHEMBL12810053 | 0.68 | DAO (0.53) | DAOALOX15 | |
| SCHEMBL12492588 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025087365-A1 | METTL3 INHIBITOR | 杭州邦顺制药有限公司 | 2025-05-01 | — | — | WO | disclosed |
| US-20250122195-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2025-04-17 | — | — | US | disclosed |
| US-12195458-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2025-01-14 | — | — | US | disclosed |
| US-20240277715-A1 | COMBINATION THERAPIES COMPRISING A METTL3 INHIBITOR AND A FURTHER ANTICANCER AGENT | STORM THERAPEUTICS LIMITED (GB) | 2024-08-22 | — | — | US | disclosed |
| EP-4346814-A1 | COMBINATION THERAPIES COMPRISING A METTL3 INHIBITOR AND A FURTHER ANTICANCER AGENT | Storm Therapeutics Ltd (GB) | 2024-04-10 | — | — | EP | disclosed |
| CN-117460508-A | Combination therapy comprising a METTL3 inhibitor and an additional anticancer agent | 斯托姆治疗有限公司 | 2024-01-26 | — | — | CN | disclosed |
| CN-116640157-A | METTL3 inhibitor and composition thereof and application of METTL3 inhibitor and composition thereof in medicine | 海思科医药集团股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230116403-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2023-04-13 | — | — | US | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| WO-2022254218-A1 | PROCESSES FOR THE PREPARATION OF INHIBITORY COMPOUNDS | STORM THERAPEUTICS LTD (GB) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022254216-A1 | COMBINATION THERAPIES COMPRISING A METTL3 INHIBITOR AND A FURTHER ANTICANCER AGENT | STORM THERAPEUTICS LTD (GB) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022254216-A1 | COMBINATION THERAPIES COMPRISING A METTL3 INHIBITOR AND A FURTHER ANTICANCER AGENT | STORM THERAPEUTICS LTD (GB) | 2022-12-08 | — | — | WO | disclosed |
| EP-4069694-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | Storm Therapeutics Ltd (GB) | 2022-10-12 | — | — | EP | disclosed |
| CN-115151540-A | Polyheterocyclic compounds as METTL3 inhibitors | 风暴治疗有限公司 | 2022-10-04 | — | — | CN | disclosed |
| WO-2021111124-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021111124-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122195-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | GAA 750/4885PKM 1809/4885DAO 331/4885 |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | GAA 750/4885PKM 1809/4885DAO 331/4885 |
| US-20230116403-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | METTL3, DIMT1, TPMT | GAA 750/4885PKM 1809/4885DAO 331/4885 |
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | GAA 750/4885PKM 1809/4885DAO 331/4885 |
| US-20240277715-A1 | COMBINATION THERAPIES COMPRISING A METTL3 INHIBITOR AND A FURTHER ANTICANCER AGENT | FLT3, METTL3, TET2 | GAA 2119/4885PKM 3415/4885DAO 2212/4885 |
| US-12195458-B2 | Polyheterocyclic compounds as METTL3 inhibitors | METTL3, DIMT1, TPMT | GAA 750/4885PKM 1809/4885DAO 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.